会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE
    • 有机氮氧化物增强血管紧张素Ⅱ拮抗剂,组合物和使用方法
    • WO2006099058A3
    • 2007-05-18
    • PCT/US2006008441
    • 2006-03-09
    • NITROMED INCGARVEY DAVID SCAI XIONGLIN CHIA-ENRANATUNGE RAMINI RSTEVENSON CHERI AWEY SHIOW-JYI
    • GARVEY DAVID SCAI XIONGLIN CHIA-ENRANATUNGE RAMINI RSTEVENSON CHERI AWEY SHIOW-JYI
    • A61K31/41C07D257/04
    • C07D257/04C07C291/02C07D213/82
    • The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin p antagonist, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (1) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin II antagonists are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.
    • 本发明描述了包含血管紧张素p拮抗剂的至少一种有机一氧化氮增强盐和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂的组合物和试剂盒。 本发明还提供了(a)治疗心血管疾病的方法; (b)治疗血管性疾病; (c)治疗糖尿病; (d)治疗由氧化应激引起的疾病; (e)治疗内皮功能障碍; (f)治疗由内皮功能障碍引起的疾病; (g)治疗肝硬化; (h)治疗先兆子痫; (j)治疗骨质疏松症; (k)治疗肾病; (1)治疗外周血管疾病; (m)治疗门静脉高压; (n)治疗眼科疾病; (o)治疗代谢综合征; 和(p)治疗高脂血症。 与血管紧张素II拮抗剂形成盐的有机一氧化氮增强化合物是有机硝酸盐,有机亚硝酸盐,亚硝基硫醇,硫堇啶,硫堇酸盐,非硝酸盐,杂环一氧化氮供体和/或氮氧化物。 杂环一氧化氮供体是呋喃糖,苏氨酸,氧杂三唑-5-酮和/或氧杂三唑-5-亚胺。
    • 9. 发明申请
    • NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    • 硝基和硝基化合物,组合物和使用方法
    • WO2004098538A2
    • 2004-11-18
    • PCT/US2004/007943
    • 2004-03-15
    • NITROMED, INC.EARL, Richard, A.GARVEY, David, S.GASTON, Ricky, D.LIN, Chia-EnRANATUNGE, Ramani, R.RICHARDSON, Stewart, K.STEVENSON, Cheri, A.
    • EARL, Richard, A.GARVEY, David, S.GASTON, Ricky, D.LIN, Chia-EnRANATUNGE, Ramani, R.RICHARDSON, Stewart, K.STEVENSON, Cheri, A.
    • A61K
    • C07J17/00C07J1/00C07J31/006C07J41/0044C07J43/00C07J43/003
    • The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and at least one nitric oxide donor compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering at least one compound of the invention that is optionally nitrosated and/or nitrosylated, in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The compounds of the invention are preferably estradiol compounds, troglitazone compounds, tranilast compounds, retinoic acid compounds, resveratol compounds, myophenolic acid compounds, acid compounds, anthracenone compounds and trapidil compounds.
    • 本发明描述了本发明的新型亚硝化和/或亚硝基化化合物及其药学上可接受的盐,以及包含至少一种本发明的亚硝基化和/或亚硝化化合物和任选的至少一种一氧化氮供体化合物和/ 或至少一种治疗剂。 本发明还提供了包含至少一种本发明的化合物,其任选被亚硝化和/或亚硝基化的新化合物,以及至少一种一氧化氮供体化合物和/或至少一种治疗剂。 本发明的化合物和组合物也可以结合到基质上。 本发明还提供治疗心血管疾病的方法,用于抑制由血液暴露于医疗器械引起的血小板聚集和血小板粘附,用于治疗由异常细胞增殖引起的病理状况; 移植排斥,自身免疫,炎症,增殖,过度增生或血管疾病; 用于减少瘢痕组织或抑制伤口收缩,特别是预防和/或治疗再狭窄的方法,通过给予至少一种任选地亚硝化和/或亚硝基化的本发明化合物与能释放硝酸的一氧化氮供体组合 在生理条件下氧化或间接地将一氧化氮递送或转移到靶位点。 本发明的化合物优选是雌二醇化合物,曲格列酮化合物,曲尼司特化合物,视黄酸化合物,白藜芦醇化合物,肌醇酸化合物,酸化合物,蒽酮化合物和捕获剂化合物。